top of page
Search

Breaking News: UPplus KBD Spray Approved for Manufacturing and Free Sale By FDA

Writer's picture: Peter XiaoPeter Xiao


UPcare Group is excited to announce that the U.S. Food and Drug Administration (FDA) has granted UPcare's UPplus KBD Spray registration (FDA  CFS ID: QBGU-BAWB) at 27 OCT 2020, allowing it to be manufactured and free sale in the United States.



"This is another great news after we got listed pm the ARTG in Australia.", said CEO Victor HUANG, "USA market is very important for us, and as of October 27, the total number of patients infected with COVID-19 in the United States has reached 8.97 million and 231,000 have died. There simply is no any medicine in the market yet except Remsidivir recently approved by FDA only for shortening the treatment cycle."


UPplus formulation has been strictly selected by the Australian 'SARS-CoV-2 Antiviral and Antiseptic Screening Program' , and UPplus compounds were given priority for testing.


UPcare adopted a pragmatic product strategy of applying complementary medicine or diet supplement registration to launch the product at the first place, which will enable consumers to use the product immediately as it has been proven safe to use during last few years' toxicity tests. UPplus KBD Spray is committed to protecting respiratory health, boosting immune system and may help many people during this tough time.


UPcare Group is discussing with the US FDA to conduct clinical trials in the near future to further verify the company's products for the treatment of SARS-CoV-2.


We are now also scheduling manufacturing in USA and looking for more distributors in North America markets, please contact us for sales and distribution opportunities at: victor@upcare.tech



About UPcare Group


UPCare Group Pty Ltd global biopharmaceutical company and a world leader in the development of pharmaceutical and medical products based on natural botanic combinations called UPplus® with focuses on COVID-19. UPcare has developed UPplus KBD Spray™ (an antiviral oral spray) and UPplus A Capsules™, (an antiviral capsule) for COVID-19 and other respiratory infections, which are complementary to vaccines and other preventative measures such as social distancing and PPE. Both UPplus® products are approved by both Australia and USA government authorities and registered for free sale.


As a leading company in the botanic based drug delivery, UPcare’s proprietary drug delivery platform Apex Biotech Research, which has been collaborating with the prestigious Monash Univeristy is being used to screening compounds, improve pharmaceuticals, to reduce toxicities and enhance their performance.

1 view0 comments

Comments


123 Whitehorse Rd

Balwyn VIC 3103, Australia

© 2024 by IRP Health.

Disclaimer: This website's information is for general purposes only. Statements related to potential therapeutic benefits or product development should not be interpreted as medical recommendations. We encourage visitors to consult with healthcare professionals for personalized advice.

bottom of page